About JSR Life Sciences

Learn what we are all about

JSR Life Sciences brings together the deep biochemical knowledge and understanding of human disease, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for our customers.

JSR supports the drug discovery and development needs of our partners with tailored solutions that identifies and applies the right tools and technologies to support their unique therapeutic programs. From de-risking molecule selection and accelerating biologic development timelines, to increasing clinical success rates and developing in vitro diagnostics, JSR Life Sciences is committed to guiding our customers’ innovative science along the path to becoming life-saving medicines.

Accelerating Our Life Sciences Footprint

We offer our partners best-in-class research products and services for outsourced drug discovery and development. With our proprietary products and services and through our affiliate companies, JSR has a global presence including 28 sites in seven countries.

Our Affiliates

We leverage the core competencies of our affiliates to create integrated solutions that are designed to guide our partners’ programs from the lab through commercialization.

Crown Bioscience
Contract research organization with advanced technology for precision medicine

Similis Bio
Similis Bio jump-starts your biosimilar program with pre-qualified analytical methods, detailed reference product characterization & off-the-shelf assets.

MBL
Biomarker discovery for companion and in vitro diagnostics

KBI Biopharma
Global contract development and manufacturing organization with advanced analytical capabilities


JSR’s specialty life science research products include:

Amsphere A3, a protein A chromatography resin for advanced protein separation

Magnosphere hydrophilic and hydrophobic microparticles for research and in vitro diagnostics use

JSR Life Sciences is a business unit of JSR Corporation, a multinational advanced materials and solutions company based in Japan.

Latest JSR Life Sciences news

KBI Biopharma、FDAによる規制査察完了および世界有数の大手製薬会社との商用製造契約を延長拡大

KBI Biopharma、FDA規制査察完了と大手製薬会社との製造契約延長を発表。契約は2029年まで延長され、2億5000万ドルの追加購入が合意。

「MEBRIGHT™ ジェニタリウム Plus DR キット」に関する 学会共催セミナー開催のお知らせ

株式会社医学生物学研究所は、2024年6月27日から神戸で「MEBRIGHT™ ジェニタリウム Plus DR キット」についてのランチョンセミナーを開催します。

免疫療法の有害事象の指標としたAnti-Integrin αVβ6自己抗体検出に関わるライセンス契約締結のお知らせ

JSR株式会社のライフサイエンス事業のグループ企業である株式会社医学生物学研究所(取締役社長 伊藤 浩毅)は、京都大学ならびに近畿大学と、免疫関連有害事象 (以下、irAE) 腸炎の指標としたAnti-Integrin αVβ6自己抗体の検出に関する特許ライセンス契約(独占型)を締結したことをお知らせいたします

Receive JSR Life Sciences news on your RSS reader.

Or subscribe through Atom URL manually